Association Between Uterine Volume and In Vitro Fertilization (IVF) Reproductive Outcomes of Infertile Patients with Adenomyosis

To explore the association between uterine volume and in vitro fertilization (IVF) reproductive outcomes of infertile patients with adeno- myosis, we performed a retrospective cohort study of infertile patients with adenomyosis who underwent IVF from January 2009 to December 2019 in our clinical center. Patients were divided into five groups according to the uterine volume before the IVF cycle. A line graph was drawn to demonstrate the linear trend of IVF reproductive outcomes with uterine volume. Univariate and multivariate analyses were used to explore the association between uterine volume of adenomyosis patients and IVF reproductive outcomes in first fresh embryo transfer (ET) cycle, first frozen-thawed embryo transfer (FET) cycle, and per ET cycle. Kaplan–Meier curves and Cox regression were conducted to evaluate the association between uterine volume and cumulative live birth. A total of 1155 infertile patients with adenomyosis were included. Clinical pregnancy rate showed no significant correlation with uterine volume in first fresh ET cycle, first FET cycle, and per ET cycle; miscarriage rate showed an upward trend with uterine volume increasement, in which the uterine volume turning point was 8 weeks of gestation; live birth rate showed a downward trend with turning point of 10 weeks of gestation. Subsequently, patients were divided into two groups (uterine volume ≤ 8 weeks of gestation vs. uterine volume > 8 weeks of gestation). Univariate and multivariate analyses showed that patients with a uterus larger than 8 weeks of gestation had a higher miscarriage rate and a lower live birth rate in all ET cycles. Kaplan–Meier curves and Cox regression demonstrated lower cumulative live birth rate in patients with a uterine volume larger than 8 weeks of gestation. IVF reproductive outcome gets worse as uterine volume increases in infertile patients with adenomyosis. Adenomyosis patients with a uterus larger than 8 weeks of gestation had a higher miscarriage rate and a lower live birth rate.

Adenomyosis · Infertility · Uterine volume · In vitro fertilization

Adenomyosis is a common gynecological disease in women of reproductive age which is characterized by endometrial glands and stroma in the normal myometrium, accompanied by hypertrophy of the surrounding myometrial smooth muscle cells [1]. The main clinical manifestations of adenomyosis include dysmenorrhea, abnormal uterine bleeding, and infertility. The results of several studies showed that the clinical pregnancy rate and live birth rate of in vitro fertilization- embryo transfer (IVF-ET) decreased in infertile patients with adenomyosis [2 –4]. However, there is currently a Wen Zhang and Ningning Pan contributed equally to the manuscript. * Caihong Ma [email protected] * Jie Qiao [email protected] 1 Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China 2 National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing 100191, China 3 Key Laboratory of Assisted Reproduction, Ministry of Education (Peking University), Beijing 100191, China 4 Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing 100191, China 5 Research Units of Comprehensive Diagnosis and Treatment of Oocyte Maturation Arrest, Chinese Academy of Medical Sciences, Beijing 100191, China 3124 Reproductive Sciences (2023) 30:3123–3131 1 3 lack of appropriate evaluation indicators to evaluate the severity degree of adenomyosis, as well as the lack of prognostic indicators for IVF reproductive outcomes in infertile patients with adenomyosis. For adenomyosis, ectopic endometrium grows diffusely in the myometrium, resulting in the enlargement of the uterus, obviously increasing anterior and posterior diameter and the uterus might often be a spherical shape. Ultrasound examination showed that the uterus was enlarged, the myometrium was thickened, and the lesion site is iso-echo or echo enhancement, with punctate hypoecho, and there is no obvious boundary between the lesion and the surround- ing. Mavrelos D et al. showed that more accumulation of adenomyosis features on ultrasound was associated with a lower clinical pregnancy rate after IVF in infertile women with adenomyosis [5 ]. Many studies have sug- gested that pretreatment with a gonadotrophin-releasing hormone agonist (GnRH-a) could reduce the volume of the uterus and thus improve the clinical pregnancy rate of infertile patients with adenomyosis [6 , 7]. Previous stud- ies by our research group have demonstrated the impact of uterine volume on reproductive outcomes in adenomyo- sis patients. We included a total of 158 infertile patients with adenomyosis, and the uterine volume exceeded 100 cm3 before frozen-thawed embryo transfer (FET) had an increased risk of miscarriage [3 , 8, 9]. The above findings suggest that the uterine volume of adenomyosis is closely related to IVF reproductive out - comes. A consensus of experts in China recommended natural pregnancy after GnRH-a pretreatment for adeno- myosis-associated infertile patients with a uterine volume smaller than 12 weeks of gestation and recommended IVF until uterine volume larger than 12 weeks of gestation [10]. However, we doubted that adenomyosis patients will miss the best opportunity for IVF if IVF was recom- mended until the uterine volume was larger than 12 weeks of gestation. The association between different uterine volumes of adenomyosis patients and IVF reproductive outcomes remains unknown. Therefore, our research team included ten years of IVF-ET clinical data of adenomyo- sis-associated infertility patients and detailly recorded the uterine volume of each patient to explore the association between uterine volume and IVF reproductive outcomes.

Study Design and Patients This was a retrospective cohort study of infertile patients with adenomyosis who underwent IVF-ET at the Repro- ductive Center of the Peking University Third Hospital from January 2009 to December 2019. This research was approved by the Ethical Review Committee of Peking Uni- versity Third Hospital (No. LM2021243). The individual consent for this retrospective analysis was waived. The inclusion criteria were as follows: Patients were diagnosed as adenomyosis by transvaginal ultrasound scans (TVS) [11], and the TVS were performed by two experi- enced sonographers; aged ≤ 45 years old at the first out- patient visit to our Reproductive Center; with the regular menstrual cycle. The criteria for sonographic diagnosis of adenomyosis are with 2 or more of the following: heteroge- neous myometrial texture with the presence of a globular asymmetric uterus, thickening of the anterior and poste - rior myometrial wall, and irregular cystic areas within the myometrium [12]. Exclusion criteria were listed as follows: patients with intrauterine adhesion, uterine malformation, submucosal leiomyoma, or ≥ 5.0 cm in diameter leiomyoma; hydrosalpinx and systemic diseases; and patients with other endocrine severe diseases, immune diseases, tumors, and abnormal chromosomes in either partner. Uterine Volume Measurement and Corresponding Gestational Weeks Each adenomyosis patient underwent gynecological ultra- sound prior to the initiation of IVF-ET. The uterine volume was calculated by using a geometric formula for a prolate ellipsoid volume: long diameter × width diameter × anter - oposterior diameter × π/6 [13]. Uterine volume and the corresponding gestational weeks were listed as follows: Uterine volume ≤ 56 cm3 was corresponding to ≤ 4 weeks of gestation, 56–90 cm3 was corresponding to 4–6 weeks of gestation, 90–130 cm3 was corresponding to 6–8 weeks of gestation, 130–180 cm3 was corresponding to 8–10 weeks of gestation, and > 180 cm3 was corresponding to > 10 weeks of gestation [14] (see Supplementary Table 1). IVF Protocol and Embryo Transfer Different controlled ovarian hyperstimulation (COH) proto- cols were administrated for adenomyosis-associated infertile patients, such as GnRH-a ultralong protocol, GnRH-a long protocol, GnRH-antagonist protocol, and minimal ovarian stimulation protocol [15]. Either recombinant follicle-stim- ulating hormone (rFSH) or human menopausal gonado- trophins (hMG) were used. Standard methods for oocyte retrieval and fertilization with conventional IVF were used. The quality of embryos was evaluated according to the Istan- bul Consensus Workshop on Embryo Assessment criteria [16]. Blastocysts were evaluated according to the Gardner morphological grading system. Embryos/blastocysts trans- fer was performed on day 3/day 5 in a fresh cycle. Other 3125Reproductive Sciences (2023) 30:3123–3131 1 3 embryos/blastocysts were vitrificated for cryopreservation. Vaginal and/or intramuscular/oral progesterone were given as luteal support. Frozen‑thawed Embryo Transfer GnRH-a pretreatment before FET was determined based on the experience of clinicians and the needs of patients. Patients with GnRH-a pretreatment were injected subcu- taneously with long-acting GnRH-a (triptorelin acetate for injection, Ipsen, French, 3.75 mg) for 1–6 months or more, starting from the 1st day to the 5th day of menstruation, once per 28–35 days. Endometrial preparation was started 28 days after the last GnRH-a injection with daily estradiol 4–6 mg, and progesterone was added when the thickness of the endometrium reached 8 mm. After 5–7 days of proges- terone treatment, one or two embryos were transferred into the uterus. A natural cycle was applied for patients without GnRH-a pretreatment. Clinical Data and Definitions The basic characteristics of the participants, such as age, body mass index (BMI), infertility type, infertility duration, gravidy, parity times, basal FSH, anti-Müllerian hormone (AMH), uterine volume before IVF cycle, COH protocol, endometrial thickness, number of embryos transferred, and transferred embryo type (cleavage embryo/blastocyst), were evaluated. Clinical pregnancy denoted evidence of at least one intrauterine gestational sac observed by ultrasonography 30 days after embryo transfer. Miscarriage was defined as the presence of an intrauterine gestational sac but no subsequent live birth after 24 weeks of gestation. Live birth was defined as the delivery of a live baby after 24 weeks of gestation. Statistical Analysis Characteristics were presented as mean ± standard deviation (SD) or median (interquartile range, IQR) for continuous vari- ables and percentages for categorical variables. Comparisons between ratios were performed using the chi-square test or Fisher’s exact test. Continuous variables were analyzed by T-tests or nonparametric tests. A line graph was drawn to explore the linear trend of IVF reproductive outcomes with uterine volume. Logistic regression models were used to esti- mate the effect of uterine volume on reproductive outcomes. Kaplan–Meier (KM) curves were made to compare the cumu- lative live birth rate between different groups. Since the num- ber of patients with ≥ 5 embryo transfer cycles was small, we analyzed the cumulative live birth rate of the patients during the first 4 embryo transfer cycles. Furthermore, multivariate Cox regression was conducted to evaluate the effect of uter- ine volume on the cumulative live birth rate. P < 0.05 was considered statistically significant. Analysis was performed using the Statistical Package for Social Sciences (SPSS), ver- sion 25.0 (IBM, Armonk, New York, USA).

Baseline Characteristics of Infertile Patients with Adenomyosis A total of 1155 infertile patients with adenomyosis were included in this study, and they were divided into five groups according to their uterine volume (presenting with corre- sponding gestational week), as shown in Supplementary Table 1. Baseline Characteristics and Reproductive Outcomes of Adenomyosis‑associated Infertile Patients with Different Uterine Volume Patients’ age gradually increased as uterine volume increased (age in each group was 33.1 years, 34.7 years, 35.0 years, 35.2 years, and 35.7 years, respectively), as did BMI (BMI in each group was 22.4 kg/m2, 23.1 kg/m 2, 23.2 kg/m 2, 23.7 kg/ m2, and 23.9 kg/m 2, respectively), with P values of 0.000 and 0.002, respectively. Infertility type, infertility duration, gravidy, basal FSH, and AMH were not statistically signifi- cant among the groups. In order to fully explore the reproductive outcomes in adenomyosis patients with different uterine volumes, our study analyzed from three perspectives: first fresh ET cycle, first FET cycle, and per ET cycle, as shown in Sup- plementary Table 2. The results are listed as follows: ① Clinical pregnancy rate showed no statistical differences in first fresh ET cycle, first FET cycle, and per ET cycle with p values of 0.143, 0.754, and 0.076, respectively. ② Miscarriage rate showed an upward trend with the increase of uterine volume, and P values in first fresh ET cycle, first FET cycle, and per ET cycle were 0.057, 0.032, and 0.002, respectively. ③ Live birth rate showed a downward trend with the increase in uterine volume, and P values were 0.022, 0.100, and 0.001, respectively. P values of miscar - riage rate and live birth rate in some comparisons showed close to 0.05 but still larger than 0.05 maybe because of the relatively small sample size in each subgroup. What is more, we identified uterine volume turning points for worse reproductive outcomes (i.e., high miscarriage rate and low live birth rate) in infertile patients with adenomyo- sis. In terms of clinical pregnancy rate, our study did not find a significant uterine volume turning point for a worse clinical pregnancy rate (Fig. 1A). As seen in Supplementary Table 2 and Fig.  1, ① uterine volume at 8 weeks of gesta- tion (130cm3) was the turning point for higher miscarriage 3126 Reproductive Sciences (2023) 30:3123–3131 1 3 rate, i.e., the miscarriage rate increased significantly in adenomyosis-associated infertile patients with uterine vol - ume > 8 weeks of gestation (Fig.  1B). ② Uterine volume at 10 weeks of gestation (180cm3) was the turning point for lower live birth rate, i.e., live birth rate decreased sig- nificantly in adenomyosis-associated infertile patients with uterine volume > 10 weeks of gestation (Fig.  1C). Considering that the miscarriage rate had significantly increased when uterine volume exceeds 8 weeks of ges- tation, we preliminary considered that uterine volume at 8 weeks of gestation was a watershed for IVF reproductive outcomes in adenomyosis-associated infertile patients, i.e., reproductive outcomes were significantly worse in adeno- myosis patients with uterine volume > 8 weeks of gestation, which was further verified by subsequent analysis. Reproductive Outcomes of Adenomyosis‑associated Infertile Patients with Uterine Volume Grouped by 8 Weeks of Gestation We divided the infertile patients with adenomyosis into two groups (uterine volume ≤ 8 weeks of gestation vs. uterine volume > 8 weeks of gestation) and compared reproduc- tive outcomes between the two groups using univariate and multivariate analyses (see Tables  1 and 2), as well as com- paring the cumulative live birth rates using KM curves (see Fig.  2) and multivariate Cox regression (Table  2). Reproductive Outcomes Between Groups – Univariate and Multivariate Analyses Adenomyosis patients with uterine volume > 8 weeks of ges- tation had higher age (34.4 ± 4.3 vs. 35.4 ± 4.1, P = 0.001) and BMI (23.0 ± 3.7 vs. 23.8 ± 3.9, P = 0.001). Infertil- ity type, infertility duration, gravidy, parity times, basal FSH, and AMH were not statistically significantly different between the two groups (see Table  1). Similarly, we analyzed the reproductive outcomes of patients from the first fresh ET cycle, first FET cycle, and per ET cycle (see Table  1). ① In terms of the first fresh ET cycle, there was no statistically significant difference in clinical pregnancy rate between the two groups (40.8% vs. 35.2%, P = 0.152); however, the miscarriage rate signifi- cantly increased (23.6% vs. 36.2%, P = 0.031) and live birth rate significantly decreased (31.2% vs. 22.4%, P = 0.017) in adenomyosis patient with uterine volume > 8 weeks of gestation (see Table  1). ② In the first FET cycle, the miscar- riage rate was higher in adenomyosis patients with uterine 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00% ≤5 6὘ 56-90὘ 90-130὘ 130-180὘ ͽ180὘ Live birthr ate Firs tI VF-ETF irst FETP er ET 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00% 45.00% ≤5 6὘ 56-90὘ 90-130὘ 130-180὘ ͽ180὘ Miscarriag er at e First IVF-ET Firs tF ET Pe rE T AB C 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% ≤5 6὘ 56-90὘ 90-130὘ 130-180὘ ͽ180὘ Clinical pregnanc yr at e Firs tI VF-ETF irst FETP er ET Fig. 1 Line graph for reproductive outcomes of adenomyosis patients with different uterine volumes. (A) Clinical pregnancy rate varied with uterine volume. (B) The miscarriage rate showed an upward trend with uterine volume increasement, and the uterine volume turning point (red arrow) was 8  weeks of gestation. (C) Live birth rate showed a downward trend with a turning point (red arrow) of 10 weeks of gestation 3127Reproductive Sciences (2023) 30:3123–3131 1 3 Table 1 Reproductive outcomes of adenomyosis-associated infertile patients with uterine volume grouped by 8 weeks of gestation – univariate analysis BMI, body mass index; SD, standard deviation; IQR, interquartile range; COH , controlled ovarian hyper - stimulation; Gn, gonadotropin Grouped by 8 weeks of gestation, n = 1155 Uterine volume(cm3) ≤ 130 > 130 P Number 891 264 Age (years), mean ± SD 34.4 ± 4.3 35.4 ± 4.1 0.001 BMI (kg/m2), mean ± SD 23.0 ± 3.7 23.8 ± 3.9 0.001 Infertility type, % 0.381   Primary infertility 496/891 (55.7%) 155/264 (58.7%)   Secondary infertility 395/891 (44.3%) 109/264 (41.3%) Infertility duration (years), median (IQR) 3.0 (2.0, 5.0) 4.0 (2.0, 5.0) 0.420 Gravidy, median (IQR) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 0.487 Parity times, median (IQR) 0.0 (0.0 0.0) 0.0 (0.0 0.0) 0.376 Basal FSH (mIU/ml), median (IQR) 6.6 (5.3, 8.3) 6.6 (4.9, 8.1) 0.092 AMH (ng/ml), median (IQR) 2.0 (1.0, 3.3) 2.4 (1.3, 3.9) 0.249 First fresh ET cycle, n = 943 Number 747 196 COH protocol, % 0.000   GnRH-a ultralong protocol 397/747 (53.1%) 163/196 (83.2%)   GnRH-a long protocol 144/747 (19.3%) 13/196 (6.6%)   Other protocols 206/747 (27.6%) 20/196 (10.2%) Gn dose (IU), median (IQR) 3300.0 (2400.0, 4350.0) 3525.0 (2837.5, 4650.0) 0.012 Gn days (day), mean ± SD 11.8 ± 2.4 11.7 ± 2.5 0.702 Transferred embryo, % 0.098   Cleavage embryo 715/747 (95.7%) 182/196 (92.9%)   Blastocyst 32/747 (4.3%) 14/196 (7.1%) No. of embryos transferred, mean ± SD 1.9 ± 0.5 1.9 ± 0.5 0.619 Endometrial thickness (mm), mean ± SD 10.7 ± 1.8 10.5 ± 1.9 0.155 Clinical pregnancy rate, % 305/747 (40.8%) 69/196 (35.2%) 0.152 Miscarriage rate, % 72/305 (23.6%) 25/69 (36.2%) 0.031 Live birth rate, % 233/747 (31.2%) 44/196 (22.4%) 0.017 First FET cycle, n = 493 Number 360 133 GnRHa pretreatment, % 102/360 (28.3%) 108/133 (81.2%) 0.000 Transferred embryo, % 0.549   Cleavage embryo 157/360 (43.6%) 54/133 (40.6%)   Blastocyst 203/360 (56.4%) 79/133 (59.4%) No. of embryos transferred, mean ± SD 1.5 ± 0.6 1.5 ± 0.6 0.367 Endometrial thickness (mm), mean ± SD 10.0 ± 1.8 9.7 ± 1.5 0.170 Clinical pregnancy rate, % 141/360 (39.2%) 58/133 (43.6%) 0.372 Miscarriage rate, % 35/141 (24.8%) 23/58 (39.7%) 0.036 Live birth rate, % 106/360 (29.4%) 35/133 (26.3%) 0.495 Per ET cycle, n = 1876 Number 1418 458 Transferred embryo, % 0.009   Cleavage embryo 1063/1418 (75.0%) 315/458 (68.8%)   Blastocyst 355/1418 (25.0%) 143/458 (31.2%) No. of embryos transferred, mean ± SD 1.8 ± 0.5 1.7 ± 0.6 0.101 Endometrial thickness (mm), mean ± SD 10.4 ± 1.8 10.1 ± 1.8 0.003 Clinical pregnancy rate, % 549/1418 (38.7%) 169/458 (36.9%) 0.487 Miscarriage rate, % 139/549 (25.3%) 68/169 (40.2%) 0.000 Live birth rate, % 410/1418 (28.9%) 101/458 (22.1%) 0.004 3128 Reproductive Sciences (2023) 30:3123–3131 1 3 volume > 8 weeks of gestation (24.8% vs. 39.7%, P = 0.036). ③ In per ET cycle, the clinical pregnancy rate was not statis- tically different between the two groups (38.7% vs. 36.9%, P = 0.487), but the miscarriage rate significantly increased (25.3% vs. 40.2%, P = 0.000) and live birth rate significantly decreased (28.9% vs. 22.1%, P = 0.004) in adenomyosis patient with uterine volume > 8 weeks of gestation. Multivariate analysis showed the same conclusions after correcting for age, BMI, embryos/blastocysts, and COH pro- tocol/GnRH-a pretreatment before FET (see Table  2). Cumulative Live Birth Rate Between Groups – Univariate and Multivariate Analyses The KM curves showed that cumulative live birth rate sig- nificantly decreased in adenomyosis patients with uterine vol- ume > 8 weeks of gestation, with p values of 0.003 (see Fig. 2). Multivariate Cox regression adjusted age and BMI and showed the same results, with p values of 0.045 (see Table 2).

This study analyzed the IVF reproductive outcomes of adenomyosis-associated infertile patients with different uterine volumes and found that adenomyosis patients with a uterus larger than 8 weeks of gestation had a higher rate Table 2 Reproductive outcomes of adenomyosis-associated infertile patients with uterine volume grouped by 8 weeks of gestation – mul- tivariate logistic analysis/multivariate Cox regression # Multivariate logistic analysis adjusting age, BMI, embryos/blas- tocysts, and COH protocol/GnRHa pretreatment before FET in first IVF-ET cycle, first FET cycle, and per ET cycle; multivariate Cox regression adjusting age, BMI in the cumulative cycle OR, odds ratio; CI, confidence interval OR 95%CI P# First fresh ET cycle Clinical pregnancy rate 0.746 0.526, 1.057 0.099 Miscarriage rate 1.807 1.035, 3.157 0.038 Live birth rate 0.637 0.432, 0.938 0.022 First FET cycle Clinical pregnancy rate 1.349 0.837, 2.174 0.219 Miscarriage rate 2.463 1.104, 5.494 0.028 Live birth rate 0.865 0.510, 1.467 0.591 Per ET cycle Clinical pregnancy rate 1.002 0.798, 1.257 0.989 Miscarriage rate 1.862 1.278, 2.711 0.001 Live birth rate 0.753 0.580, 0.977 0.033 Cumulative cycle Cumulative live birth rate 0.794 0.634, 0.995 0.045 Fig. 2 Kaplan–Meier curves comparing cumulative live birth rate between two groups. The cumulative live birth rate sig- nificantly decreased in adeno- myosis patients with uterine volume > 8 weeks of gestation, with a p value of 0.003 P=0.003 3129Reproductive Sciences (2023) 30:3123–3131 1 3 of miscarriage and a lower rate of live birth. In addition, our study confirmed this finding from four perspectives (first fresh ET cycle, first FET cycle, per ET cycle, and cumula- tive live birth rate). It is widely accepted that adenomyosis could affect IVF reproductive outcomes. Younes G conducted a meta-analysis and found that implantation, clinical pregnancy, ongoing pregnancy, and live birth were significantly lower and the miscarriage rate was higher in adenomyosis patients than in controls [17]. Zhang XP also found that the early miscar - riage rate in the adenomyosis group was significantly higher than that in the control group, and the live birth rate was lower [18]. Both of the above studies confirmed the effect of adenomyosis on IVF reproductive outcomes; however, it is unclear whether different types of adenomyosis affect IVF reproductive outcomes to different degrees. The relation- ship between infertility and clinical subtypes of adenomyo- sis has also been gradually concerned. Clinical subtypes of adenomyosis included focal/diffuse type and internal/exter- nal type. Focal adenomyosis (including adenomyoma) is classified when typical ultrasonographic adenomyotic signs are circumscribed in aggregates and surrounded by normal myometrium. Diffuse adenomyosis is classified when typical alterations at TVS spread throughout the myometrium [19]. Internal adenomyosis was defined as a junctional zone(JZ) max of at least 12 mm and the ratio of the JZmax to the myometrial thickness > 40%. External adenomyosis was defined as an adenomyosis lesion located in the outer shell of the uterus, separated from the JZ, which remained intact and with preserved healthy muscular structures between the adenomyosis and the JZ [20]. Bourdon M conducted a single-center cross-sectional study and found that the pres- ence of focal adenomyosis of the outer myometrium (diag- nosed by magnetic resonance imaging) was associated with primary infertility; however, diffuse adenomyosis was not found to be associated with infertility [21]. What is more, they also explored the relationship between internal/external adenomyosis and primary infertility and found that external adenomyosis has a higher proportion of primary infertility than internal adenomyosis [20]. However, the relationship between clinical subtypes of adenomyosis and IVF repro- ductive outcomes is unclear, and whether there are clinical indicators that could predict IVF reproductive outcomes that deserve to be further explored. There is a lack of effective predictors of reproductive out- comes in adenomyosis-associated infertile patients undergo- ing IVF. Adenomyosis is often accompanied by an increase in uterine volume, and as the lesions accumulate, the uterine volume also increases gradually. Uterine volume may play an important role in predicting IVF reproductive outcomes in adenomyosis. Our research group has previously con- ducted a series of studies on uterine volume and has proven that uterine volume of adenomyosis had adverse effects on IVF-ET and FET reproductive outcomes, and it was recom- mended to reduce uterine volume as much as possible before embryo transfer [8, 22]. In addition to the consideration of adenomyosis uterine volume before ET, we have always encountered the following question in clinical practice: How about the clinical pregnancy rate, miscarriage rate, live birth rate, and cumulative live birth rate of adenomyosis patients undergoing IVF with different uterine volumes? Therefore, this study addressed the clinical issue by describing the reproductive outcomes of IVF in adenomyosis-associated infertile patients with different uterine volumes before the IVF cycle. What is more, we identified a turning point (uter- ine volume at 8 weeks of gestation) for worse reproductive outcomes, i.e., adenomyosis patients with a uterus larger than 8 weeks of gestation had a higher miscarriage rate and a lower live birth rate. The reason why uterine volume is closely correlated with IVF reproductive outcome in adenomyosis is that, to some extent, the uterine volume represents the accumulation of adenomyosis lesions or the severity of adenomyosis. Adeno- myosis itself could cause infertility in a variety of approaches, including an enlarged uterine cavity, dysperistalsis of the uterus resulting in impaired sperm transport [23], the chronic inflammatory cells and inflammatory molecules caused by infiltration of ectopic endometrial glands [9], the increasing estrogen in eutopic endometrium caused by the overexpres- sion of aromatase P450 [24], and alterations of endometrial receptivity-related molecules, such as osteopontin, integ- rin β3, leukemia-inhibiting factor, and the HOXA-10 gene during the implantation window [7 ]. Adenomyosis uterine volume increasement indicates the accumulation of lesions and further deterioration of molecular expression and tissue function, which may have a stronger adverse effect on IVF reproductive outcome. Clinically, we found that GnRH-a could improve reproductive outcomes in adenomyosis. Park CW found that GnRH-a pretreatment could reduce uterine volume and increase the clinical pregnancy rate of infertile patients with adenomyosis [7]. Studies by our research team have also shown that GnRH-a pretreatment before FET reduced the mis- carriage rate and improved the live birth rate among infertile women with adenomyosis whose uterine volume was 56–100 cm3 [25]. However, the optimal GnRH-a treatment cycles in FET and fresh ET cycles need to be further validated in sub- sequent studies. In addition to uterine volume, the relationship between other ultrasound indicators of adenomyosis and IVF reproduc- tive outcome deserves to be further explored and analyzed, such as the clinical subtypes (focal/diffuse or internal/exter- nal) of adenomyosis. Ultrasound indicators of adenomyosis include the presence of myometrial cysts, fan-shaped echo, hyperechoic islets, globular uterus, thickest/thinnest ratio for uterine wall, maximum width of the junctional zone in the sagittal plane, and irregular appearance of the junctional zone 3130 Reproductive Sciences (2023) 30:3123–3131 1 3 [26–29]. Follow-up studies may further explore the relation- ship between the above ultrasound indicators or a combina- tion of ultrasound indicators and reproductive outcomes of IVF in adenomyosis to provide evidence to support the best clinical decision. The strengths of this study were listed as follows. First, this study innovatively identified a turning point of uterine volume (uterine volume at 8 weeks of gestation) for worse IVF reproduc- tive outcomes and found that adenomyosis patients with a uterus larger than 8 weeks of gestation had a higher miscarriage rate and a lower live birth rate. Second, the sample size of this study is large, and a total of 1155 infertile patients with adenomyosis were included, which increase the credibility of the conclusions. The

of this study is that it is a retrospective study, which requires further confirmation by subsequent prospective studies.

IVF reproductive outcome gets worse as uterine volume increases in infertile patients with adenomyosis. Adenomyosis patients with a uterus larger than 8 weeks of gestation had a higher miscarriage rate and a lower live birth rate. Supplementary Information The online version contains supplemen- tary material available at https:// doi. org/ 10. 1007/ s43032- 023- 01210-2. Funding This study was supported by the National Natural Science Foundation of China (No. 81521002), the major consulting research project of the Chinese Academy of Engineering (No. 2020-XZ-22), the CAMS Innovation Fund for Medical Sciences (2019-I2M-5–001), and the National Natural Science Foundation of China (No.82001510). Data Availability The data that support the findings of this study are available on request from the corresponding author upon reasonable request. Declarations Competing Interests The authors declare no competing interests. Open Access This article is licensed under a Creative Commons Attri- bution 4.0 International License, which permits use, sharing, adapta- tion, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

1. Brosens JJ, Barker FG, de Souza NM. Myometrial zonal differen- tiation and uterine junctional zone hyperplasia in the non-pregnant uterus. Hum Reprod Update. 1998;4:496–502. 2. Yan L, Ding L, Tang R, Chen ZJ. Effect of adenomyosis on in vitro fertilization/intracytoplasmic sperm injection outcomes in infertile women: a retrospective cohort study. Gynecol Obstet Invest. 2014;77:14–8. 3. Salim R, Riris S, Saab W, Abramov B, Khadum I, Serhal P. Adenomyosis reduces pregnancy rates in infertile women under - going IVF. Reprod Biomed Online. 2012;25:273–7. 4. Nirgianakis K, Kalaitzopoulos DR, Schwartz ASK, Spaander - man M, Kramer BW, Mueller MD, et al. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a sys - tematic review and meta-analysis. Reprod Biomed Online. 2021;42:185–206. 5. Mavrelos D, Holland TK, O’Donovan O, Khalil M, Ploum- pidis G, Jurkovic D, et al. The impact of adenomyosis on the outcome of IVF-embryo transfer. Reprod Biomed Online. 2017;35:549–54. 6. Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD. Long-term effects of gonadotropin-releasing hormone agonists and add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol. 2018;31:376–81. 7. Park CW, Choi MH, Yang KM, Song IO. Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med. 2016;43:169–73. 8. Li X, Pan N, Zhang W, Wang Y, Ge Y, Wei H, et al. Association between uterine volume and pregnancy outcomes in adenomyo- sis patients undergoing frozen-thawed embryo transfer. Reprod Biomed Online. 2021;42:384–9. 9. Tremellen KP, Russell P. The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. II: adenomyosis and macrophages. J Reprod Immunol. 2012;93:58–63. 10. Chinese expert consensus writing group for the diagnosis and treatment of adenomyosis-associated infertility. Chinese expert consensus on diagnosis and treatment of adenomyosis-associated infertility. Chinese J Reprod Contr. 2021;41:287–95. 11. Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accu- racy of transvaginal sonography for the diagnosis of adenomyo- sis: systematic review and metaanalysis. Am J Obstet Gynecol. 2009;201(107):e1-6. 12. Atri M, Reinhold C, Mehio AR, Chapman WB, Bret PM. Aden- omyosis: US features with histologic correlation in an in-vitro study. Radiology. 2000;215:783–90. 13. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clini- cal effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol. 2008;198(373):e1-7. 14. Sheth SS, Hajari AR, Lulla CP, Kshirsagar D. Sonographic evaluation of uterine volume and its clinical importance. J Obstet Gynaecol Res. 2017;43:185–9. 15. Liu N, Ma Y, Li R, Jin H, Li M, Huang X, et al. Comparison of follicular fluid amphiregulin and EGF concentrations in patients undergoing IVF with different stimulation protocols. Endocrine. 2012;42:708–16. 16. The Istanbul consensus workshop on embryo assessment. pro- ceedings of an expert meeting. Hum Reprod (Oxford England). 2011;26:1270–83. 17. Younes G, Tulandi T. Effects of adenomyosis on in vitro fer - tilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108:483-90.e3. 18. Zhang XP, Zhang YF, Shi R, Zhang YJ, Zhang XL, Hu XM et al. Pregnancy outcomes of infertile women with ultrasound-diag- nosed adenomyosis for in vitro fertilization and frozen-thawed embryo transfer. Arch Gynecol Obstet. 2021;304:1089–96. 19. Exacoustos C, Morosetti G, Conway F, Camilli S, Martire FG, Lazzeri L, et al. New sonographic classification of adenomyosis: 3131Reproductive Sciences (2023) 30:3123–3131 1 3 do type and degree of adenomyosis correlate to severity of symp- toms? J Minim Invasive Gynecol. 2020;27:1308–15. 20. Bourdon M, Oliveira J, Marcellin L, Santulli P, Bordonne C, MaitrotMantelet L, et al. Adenomyosis of the inner and outer myometrium are associated with different clinical profiles. Hum Reprod (Oxford England). 2021;36:349–57. 21. Bourdon M, Santulli P, Oliveira J, Marcellin L, Maignien C, Melka L, et al. Focal adenomyosis is associated with primary infertility. Fertil Steril. 2020;114:1271–7. 22. Li X, Pan N, Zhang W, Wang Y, Ge Y, Wei H, et al. Effect of uter- ine volume on fresh embryo transfer outcomes in infertile patients with adenomyosis. Chinese J Reprod Contracept. 2021;41:231–6. 23. Kissler S, Hamscho N, Zangos S, Wiegratz I, Schlichter S, Men- zel C, et al. Uterotubal transport disorder in adenomyosis and endometriosis – a cause for infertility. BJOG: An Int J Obstet Gynaecol. 2006;113:902–8. 24. Brosens J, Verhoeven H, Campo R, Gianaroli L, Gordts S, Haze- kamp J, et al. High endometrial aromatase P450 mRNA expres - sion is associated with poor IVF outcome. Hum Reprod (Oxford England). 2004;19:352–6. 25. Zhang W, Han B, Ma C, Qiao J. Effect of GnRH-a pretreatment before frozen-thawed embryo transfer on pregnancy outcome of adenomyosis-associated infertile patients with 56 cm(3) ≤ uterine volume ≤100 cm(3). Ann Transl Med. 2022;10:509. 26. Tellum T, Nygaard S, Skovholt EK, Qvigstad E, Lieng M. Devel- opment of a clinical prediction model for diagnosing adenomyo- sis. Fertil Steril. 2018;110:957-64.e3. 27. Bazot M, Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertil Steril. 2018;109:389–97. 28. Rasmussen CK, Hansen ES, Ernst E, Dueholm M. Two- and three- dimensional transvaginal ultrasonography for diagnosis of adenomyo- sis of the inner myometrium. Reprod Biomed Online. 2019;38:750–60. 29. Munro MG. Classification and reporting systems for adenomyosis. J Minim Invasive Gynecol. 2020;27:296–308. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.